Global Narcolepsy Drugs Market (2021 to 2030) - by Disease, Therapeutic Type and Region - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Narcolepsy Drugs Market by Disease and Therapeutic Type: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

The narcolepsy drugs market was valued at $2,680.06 million in 2020, and is projected to reach $6,667.80 million by 2030, registering a CAGR of 9.6% from 2021 to 2030.

Narcolepsy is mainly a long-term neurological disorder characterized by a classic tetrad of excessive daytime sleepiness with irresistible sleep attacks, cataplexy (sudden bilateral loss of muscle tone), hypnagogic hallucination, and sleep paralysis. Around 70% individuals experience episodes of sudden loss of muscle strength, this is often referred to as cataplexy, which can be brought on by strong emotions. Less commonly, there may be inability to move or vivid hallucinations when falling asleep or waking up. People with narcolepsy tend to sleep about the same number of hours per day as people without, but the quality of sleep tends to be worse.

Narcolepsy is a rare and under-diagnosed chronic condition affecting both males and females equally. The severity of the disease and rise in number of individuals being affected by narcolepsy are the factors that drive the market growth. Furthermore, the availability of reimbursement process for FDA-approved prescription medicines help increase the demand for these drugs. However, lack of awareness regarding the diagnosis and treatment availability is predicted to hinder the market growth. There is an increase in the number of programs organized by various organizations mainly due to surge in awareness, which is anticipated to provide lucrative opportunities for the market growth.

The narcolepsy drugs market is segmented on the basis of disease type, therapeutics type, and region. By disease type, the market is classified into daytime extreme sleepiness, cataplexia, and other disease type. By therapeutics type, the market is divided into central nervous system stimulants, tricyclic antidepressants, sodium oxybate, selective serotonin reuptake inhibitor, and other therapeutic type. By region, the global narcolepsy drugs market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

• The study provides an in-depth analysis of the global Narcolepsy drugs market along with the current trends and future estimations to elucidate the imminent investment pockets.
• A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
• Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
• Extensive analysis of the key segments of the industry helps to understand the products and end users of Narcolepsy drugs used across the globe.
• Key market players and their strategies have been analysed to understand the competitive outlook of the market.

Market Dynamics

Drivers

• Increase in global prevalence of narcolepsy
• Narcolepsy awareness programs and services
• Presence of reimbursement policies regarding narcolepsy

Restraints

• Adverse effects and risks related to narcolepsy drugs
• Delayed diagnosis or misdiagnosis

Opportunity

• Untapped markets in the developing countries

Key Players

• Arena Pharmaceuticals, Inc.
• Bioprojet Company
• Graymark Healthcare, Inc.
• Hikma Pharmaceuticals PLC
• Jazz Pharmaceuticals plc
• Ligand Pharmaceuticals Incorporated
• Shionogi Inc.
• Takeda Pharmaceutical Company Limited
• Novartis International AG
• Teva Pharmaceutical Industries Limited

For more information about this report visit https://www.researchandmarkets.com/r/uipo71

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900